EHA 2018 | Advances in targeted therapies for ALL

David Marks

Speaking from the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden, David Marks, MBBS, PhD, FRACP, FRCPath, of University Hospitals Bristol NHS Foundation Trust, Bristol, UK, discusses the newest and most promising targeted ALL therapies. Prof. Marks discusses blinatumomab, which has shown impressive results in establishing MRD negativtiy, and CAR T-cells, which may offer the hope of long-term survival to patients who were previously considered to be incurable.

Share this video